Posted by Michael Wonder on 25 May 2021
European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
25 May 2021 - Idorsia was informed by the Janssen that the European Commission has approved Ponvory (ponesimod) for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.
Idorsia and Actelion have entered into a revenue-sharing agreement in respect to ponesimod. Under the terms of the revenue-sharing agreement, Idorsia is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion.
